Select Bibliography

Filter by any of these (after searching):

Sanford, Ben

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 35 items

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013

Abstract - Secondary - Primary - Leukemia - C10403

Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia

Alachkar, Houda , Fulton, Noreen , Sanford, Ben , Malnassy, Greg ... - - Pharmacogenomics J. - 2017

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-10102

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008

Manuscript - Secondary - Primary - Leukemia - CALGB-8461 , CALGB-9720

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720

Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary - Primary - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017

Manuscript - Primary - Primary - Leukemia - CALGB-10503

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017

Manuscript - Primary - Primary - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary - Primary - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary - Primary - GU - A031203

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018

Manuscript - Secondary - Primary - GU - A031203

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008

Manuscript - Secondary - Primary - GU - CALGB-9682

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008

Manuscript - Secondary - Primary - GU - CALGB-159807 , CALGB-9682

Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603)

Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original - Primary - Leukemia - Z901101

Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study

Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480.

George, Daniel J , Halabi, Susan , Shepard, Timothy F , Sanford, Ben ... - - Clin. Cancer Res. - 2005

Manuscript - Primary - Primary - GU - INT-0159

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)

Gupta, Pankaj , Mulkey, Flora , Hasserjian, Robert P. ... - - Invest New Drugs - 2013

Manuscript - Primary - Primary - Leukemia - CALGB-10105

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).

Klepin, Heidi D. , Ritchie, Ellen K. , Sanford, Ben L. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Older Adult - CALGB-361006

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).

Klepin, Heidi D , Ritchie, Ellen , Major-Elechi, Brittny ... - - J Geriatr Oncol - 2020

Manuscript - Primary - Primary - Older Adult - CALGB-361006

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017

Abstract - Secondary - Primary - Leukemia - CALGB-10603

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Larson, Richard A , Mandrekar, Sumithra J , Huebner, Lucas J ... - - Leukemia - 2021

Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Application of multi-state models in cancer clinical trials

Le-Rademacher, Jennifer G , Peterson, Ryan A , Therneau, Terry M ... - - Clin Trials - 2018

Manuscript - No-Endpoint - Other - Leukemia - A151732 , CALGB-10603

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

Mohler, James L. , Halabi, Susan , Ryan, Stephen T. , Al-Daghmin, Ali ... - - Prostate Cancer Prostatic Dis. - 2019

Manuscript - Primary - Long-Term-Followup - GU - CALGB-9687

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Smith, Matthew R. , Halabi, Susan , Ryan, Charles J. , Hussain, Arif ... - - J. Clin. Oncol - 2014

Manuscript - Primary - Primary - GU - CALGB-90202

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Stock, Wendy , La, Mei , Sanford, Ben , Bloomfield, Clara D. ... - - Blood - 2008

Manuscript - Secondary-not-in-original - Meta-Analysis - Leukemia - CALGB-8811 , CALGB-9331 , CALGB-19802 , CALGB-8461 , CALGB-9111 , CALGB-9511

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Stock, Wendy , Luger, Selina M. , Advani, Anjali S. , Yin, Jun ... - - Blood - 2019

Manuscript - Primary - Primary - Leukemia - CALGB-10403

Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014

Abstract - Primary - Preliminary - Leukemia - CALGB-10403

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Stone, Richard M. , Mandrekar, Sumithra J. , Sanford, Ben L. ... - - N. Engl. J. Med. - 2017

Manuscript - Primary - Primary - Leukemia - CALGB-10603

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance])

Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2015

Abstract - Secondary - Primary - Leukemia - CALGB-10603

High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Stone, Richard M. , Moser, Barry , Sanford, Ben , Schulman, Philip ... - - Leuk Res - 2011

Manuscript - Primary - Primary - Leukemia - CALGB-19902

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina ... - - Blood Adv - 2017

Manuscript - Primary - Primary - Leukemia - CALGB-11001

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001).

Uy, Geoffrey L. , Mandrekar, Sumithra , Laumann, Kristina ... - ASH - Blood - 2015

Abstract - Primary - Primary - Leukemia - CALGB-11001

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013

Abstract - Primary - Preliminary - Leukemia - CALGB-11001

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Voorhees, Peter M. , Orlowski, Robert Z. , Mulkey, Flora ... - - Br. J. Haematol. - 2015

Manuscript - Primary - Primary - Leukemia - CALGB-10301

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Wetzler, Meir , Sanford, Ben L. , Kurtzberg, Joanne ... - - Blood - 2007

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9511